ES2270120T3 - Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. - Google Patents

Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. Download PDF

Info

Publication number
ES2270120T3
ES2270120T3 ES03773451T ES03773451T ES2270120T3 ES 2270120 T3 ES2270120 T3 ES 2270120T3 ES 03773451 T ES03773451 T ES 03773451T ES 03773451 T ES03773451 T ES 03773451T ES 2270120 T3 ES2270120 T3 ES 2270120T3
Authority
ES
Spain
Prior art keywords
baselineskip
sequence
seq
protein
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03773451T
Other languages
English (en)
Spanish (es)
Inventor
Claas Junghans
Matthias Schroff
Christiane Juhls
Detlef Oswald
Prof. Hans Lutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologen AG filed Critical Mologen AG
Application granted granted Critical
Publication of ES2270120T3 publication Critical patent/ES2270120T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES03773451T 2002-09-23 2003-09-19 Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina. Expired - Lifetime ES2270120T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10244863 2002-09-23
DE10244863 2002-09-23

Publications (1)

Publication Number Publication Date
ES2270120T3 true ES2270120T3 (es) 2007-04-01

Family

ID=32038184

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03773451T Expired - Lifetime ES2270120T3 (es) 2002-09-23 2003-09-19 Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina.

Country Status (9)

Country Link
US (1) US7915035B2 (https=)
EP (1) EP1553977B1 (https=)
JP (1) JP4411213B2 (https=)
AT (1) ATE335507T1 (https=)
AU (1) AU2003281917A1 (https=)
DE (2) DE50304603D1 (https=)
DK (1) DK1553977T3 (https=)
ES (1) ES2270120T3 (https=)
WO (1) WO2004028562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
SMT201900129T1 (it) * 2011-07-20 2019-05-10 Centre Nat Rech Scient Vaccino ricombinante contro il virus della leucemia felina contenente un gene ottimizzato dell'involucro del virus della leucemia felina
CA3080430A1 (en) 2017-11-06 2019-06-13 Intervet International B.V. Feline calicivirus vaccine
JP7731670B2 (ja) * 2017-11-06 2025-09-01 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
EP1432805B1 (de) * 2001-10-02 2005-05-18 Mologen AG Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose

Also Published As

Publication number Publication date
WO2004028562A3 (de) 2004-06-03
AU2003281917A8 (en) 2004-04-19
WO2004028562A2 (de) 2004-04-08
EP1553977B1 (de) 2006-08-09
DK1553977T3 (da) 2006-11-27
EP1553977A2 (de) 2005-07-20
DE10393824D2 (de) 2005-08-11
ATE335507T1 (de) 2006-09-15
JP4411213B2 (ja) 2010-02-10
DE50304603D1 (de) 2006-09-21
US7915035B2 (en) 2011-03-29
JP2006511211A (ja) 2006-04-06
AU2003281917A1 (en) 2004-04-19
US20060240034A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
JP7548902B2 (ja) アフリカ豚熱ウイルスワクチン
KR102581951B1 (ko) B형 간염 바이러스 코어 단백질 및 표면 항원 단백질 및 이를 포함하는 백신
US6465438B1 (en) Nucleic acid vaccination for parvoviral infections
US20040228842A1 (en) Compositions and methods for cytomegalovirus treatment
KR101891195B1 (ko) 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
CZ15999A3 (cs) Formulace polynukleotidové vakciny koček
KR102742526B1 (ko) 암 백신 및 이를 이용하는 치료 방법
EA023892B1 (ru) Иммуногенные белки вируса человеческой папилломы и способы их применения
Golshani et al. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen
ES2363079T3 (es) Vacuna que comprende gp120 y nef y/o tat para la inmunización contra el vih.
EP1017283B1 (en) Polynucleotide vaccine formulations
Zinckgraf et al. Modulating gene expression using DNA vaccines with different 3′-UTRs influences antibody titer, seroconversion and cytokine profiles
ES2270120T3 (es) Vacuna contra infecciones causadas por oncovirus tales como el virus de la leucemia felina.
ES2298829T3 (es) Agente para el tratamiento de infecciones por leishmania.
ES2282156T3 (es) Vacuna de acido nucleico.
US20250134979A1 (en) Dna vaccine against leishmaniasis
US8465748B2 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
CA2336992A1 (en) Polynucleotide vaccine formulations
CN101379078A (zh) 爱泼斯坦-巴尔病毒相关疾病的治疗
Li et al. CpG DNA enhances the immune responses elicited by the DNA vaccine against foot-and-mouth disease virus in guinea pigs
Moynier et al. Characterization of humoral immune responses induced by immunization with plasmid DNA expressing HIV-1 Nef accessory protein
WO2015123307A1 (en) Methods and compositions for transgene expression in a herpesvirus vector system
IT201900016736A1 (it) Antigeni fusi alla proteina Profilin-like di Toxoplasma Gondii (PFTG) e loro uso nella vaccinazione preventiva e terapeutica.
HK1108115A1 (en) Sars vaccine based on replicative vaccinia virus vector
HK1108115B (en) Sars vaccine based on replicative vaccinia virus vector